Latest News
ASCO and EHA highlights in myeloma and AL amyloidosis
The American Society of Clinical Oncology Annual Meeting (ASCO2020) is the largest and one of the most important congresses for the oncology community. Many myeloma and AL amyloidosis updates were presented at this congress which was held from 29 to 31 May 2020. Two weeks later, the 25th edition of the European Hematology Association’s annual…
MPE COVID-19 Scholarship Programme
As part of the work that Myeloma Patients Europe (MPE) is doing to provide members with support during the COVID-19 pandemic, MPE is extending the MPE Scholarship and Capacity Building Programme. Through this extension, MPE will be offering up to 10 scholarships between 2.500 and 5.000€ to develop or adapt programmes or activities related…
EHA 2020 – Subcutaneous daratumumab shows improved clinical outcomes in AL amyloidosis
New data of the ANDROMEDA clinical trial has been presented today in the late breaking session at the 25th European Hematology Association (EHA) Annual Congress which is happening virtual from 11 to 21 June. This study evaluates subcutaneous (SC) daratumumab in combination with cyclophosphamide, bortezomib, and dexamethasone (D-CyBorD) compared to CyBorD alone in newly diagnosed patients with AL amyloidosis. Light chain (AL) amyloidosis is…
- MO
- TU
- WE
- TH
- FR
- SA
- SU
- 23
- 24
- 25
- 26
- 27
- 28
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 1
- 2
- 3
- 4
- 5